Precision BioSciences Says USPTO to Re-examine Cellectis Patents | GenomeWeb

NEW YORK (GenomeWeb News) – Precision BioSciences today said that the US Patent and Trademark Office is reexamining two patents that have been licensed to Cellectis and that are part of ongoing litigation between the two firms.

The patents — US Nos. 7,214,536 and 6,833,252 — are owned by the Institut Pasteur and the Universite Pierre et Marie Curie and have been licensed to Cellectis. They are among 13 issued US patents that Cellectis is asserting against Precision BioSciences.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.